FLUOXETINE HYDROCHLORIDE for solution

Држава: Сједињене Америчке Државе

Језик: Енглески

Извор: NLM (National Library of Medicine)

Купи Сада

Активни састојак:

FLUOXETINE HYDROCHLORIDE (UNII: I9W7N6B1KJ) (Fluoxetine - UNII:01K63SUP8D)

Доступно од:

Upsher-Smith Laboratories, LLC

Пут администрације:

ORAL

Тип рецептора:

PRESCRIPTION DRUG

Терапеутске индикације:

Fluoxetine is indicated for the treatment of: - Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1)] . - Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2)] . - Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3)] . - Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4)] . Fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. The use of MAOIs intended to treat psychiatric disorders with fluoxetine or within 5 weeks of stopping treatment with fluoxetine is contraindicated because of an increased risk of serotonin syndrome. The use of fluoxetine within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contrai

Резиме производа:

Fluoxetine oral solution, USP (20 mg per 5 mL), clear, colorless liquid with spearmint flavor, is available in the following oral dosage forms: Dispense in a tight, light-resistant container. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect from light.

Статус ауторизације:

Abbreviated New Drug Application

Информативни летак

                                FLUOXETINE HYDROCHLORIDE- FLUOXETINE HYDROCHLORIDE FOR SOLUTION
Upsher-Smith Laboratories, LLC
----------
MEDICATION GUIDE
Fluoxetine Oral Solution, USP (floo ox' e teen)
Read the Medication Guide that comes with fluoxetine before you start
taking it and each time you get a
refill. There may be new information. This Medication Guide does not
take the place of talking to your
healthcare provider about your medical condition or treatment. Talk
with your healthcare provider if there
is something you do not understand or want to learn more about.
What is the most important information I should know about fluoxetine?
Fluoxetine and other antidepressant medicines may cause serious side
effects, including:
1.
Suicidal thoughts or actions:
•
Fluoxetine and other antidepressant medicines may increase suicidal
thoughts or actions in
some children, teenagers, or young adults within the first few months
of treatment or when
the dose is changed.
•
Depression or other serious mental illnesses are the most important
causes of suicidal
thoughts or actions.
•
Watch for these changes and call your healthcare provider right away
if you notice:
•
New or sudden changes in mood, behavior, actions, thoughts, or
feelings, especially
if severe.
•
Pay particular attention to such changes when fluoxetine is started or
when the dose
is changed.
Keep all follow-up visits with your healthcare provider and call
between visits if you are worried
about symptoms.
Call your healthcare provider right away if you have any of the
following symptoms, or call 911 if
an emergency, especially if they are new, worse, or worry you:
•
attempts to commit suicide
•
acting on dangerous impulses
•
acting aggressive or violent
•
thoughts about suicide or dying
•
new or worse depression
•
new or worse anxiety or panic attacks
•
feeling agitated, restless, angry or irritable
•
trouble sleeping
•
an increase in activity or talking more than what is normal for you
•
other unusual changes in behavior or mood
Call your healthcare provid
                                
                                Прочитајте комплетан документ
                                
                            

Карактеристике производа

                                FLUOXETINE HYDROCHLORIDE- FLUOXETINE HYDROCHLORIDE FOR SOLUTION
UPSHER-SMITH LABORATORIES, LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
FLUOXETINE ORAL
SOLUTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
FLUOXETINE ORAL
SOLUTION.
FLUOXETINE ORAL SOLUTION
INITIAL U.S. APPROVAL: 1991
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
INCREASED RISK OF SUICIDAL THINKING AND BEHAVIOR IN CHILDREN,
ADOLESCENTS, AND YOUNG
ADULTS TAKING ANTIDEPRESSANTS (5.1). MONITOR FOR WORSENING AND
EMERGENCE OF SUICIDAL
THOUGHTS AND BEHAVIORS (5.1).
RECENT MAJOR CHANGES
Warnings and Precautions, Serotonin Syndrome (5.2)
07/2023
Warnings and Precautions (5.7)
07/2023
INDICATIONS AND USAGE
Fluoxetine is a selective serotonin reuptake inhibitor indicated for:
Acute and maintenance treatment of Major Depressive Disorder (MDD) (1)
Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD)
(1)
Acute and maintenance treatment of Bulimia Nervosa (1)
Acute treatment of Panic Disorder, with or without agoraphobia (1)
DOSAGE AND ADMINISTRATION
INDICATION
ADULT
PEDIATRIC
MDD (2.1)
20 mg/day in a.m. (initial dose)
10 to 20 mg/day (initial dose)
OCD (2.2)
20 mg/day in a.m. (initial dose)
10 mg/day (initial dose)
Bulimia Nervosa (2.3)
60 mg/day in a.m.
‒
Panic Disorder (2.4)
10 mg/day (initial dose)
‒
A lower or less frequent dosage should be used in patients with
hepatic impairment, the elderly, and for
patients with concurrent disease or on multiple concomitant
medications (2.7)
DOSAGE FORMS AND STRENGTHS
Oral solution: 20 mg per 5 mL (3)
CONTRAINDICATIONS
_Serotonin Syndrome and MAOIs:_ Do not use MAOIs intended to treat
psychiatric disorders with
fluoxetine or within 5 weeks of stopping treatment with fluoxetine. Do
not use fluoxetine within 14 days
of stopping an MAOI intended to treat psychiatric disorders. In
addition, do not start fluoxetine in a
patient who is being treated with lin
                                
                                Прочитајте комплетан документ
                                
                            

Обавештења о претрази у вези са овим производом

Погледајте историју докумената